$Biohaven (BHVN.US)$ Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) • Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes. ◦ Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment. • Tror...
Biohaven股票讨论
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
• Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.
◦ Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.
• Tror...
加拿大皇家银行升级雅诗兰黛等级 $雅诗兰黛 (EL.US)$ 从行业表现中跑赢大盘
加拿大皇家银行表示,它认为风险/回报具有吸引力。
“我们正在将EL股票上调至跑赢大盘。目前,我们认为每股收益和投资者情绪已经陷入困境,并认为风险回报状况向好倾斜。”
摩根士丹利重申特斯拉 $特斯拉 (TSLA.US)$ 像超重一样
摩根·斯塔...
» 前20名持股数:58.46%
» 季度环比变化:28.47%
前20名持仓:
$Cerevel Therapeutics Holdings (CERE.US)$
$爱美医疗 (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$美敦力 (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$